![Pinterest](https://pinterest.com/pin/create/button/?url=https://uknews.evprotec.com/a-new-jab-may-prevent-my-daughter-suffering-breast-cancer-like-i-did/&media=https://uknews.evprotec.com/wp-content/uploads/2023/07/KOARAAC75VGBLOBMMVMKYWQW2M.jpg&description='We do believe that, should all the appropriate clinical trials succeed, we can eliminate triple negative breast cancer," says Dr Amit Kumar. Photo / 123RF A ground-breaking new vaccine being trialled in America could save thousands of women from catching triple negative breast cancer (TNBC). Imagine having a simple vaccination that could protect you from the disease that affects one in seven women in the UK, and is the leading cause of death for women aged 35-49. It sounds like a futuristic fantasy, but recently a flurry of headlines announced that a breast cancer vaccine could be available as soon as 2030. Let's look at the facts: the vaccine in question is specifically for triple negative breast cancer (TNBC), and has so far only been tested on women who have had successful treatment for primary TNBC, but are at high risk of recurrence. This type of breast cancer only accounts for around 10-15 per cent of diagnoses, but it's particularly aggressive and causes 30 per cent of breast cancer deaths. Known as 'triple negative' because it lacks the three main hormone receptors and proteins usually targeted in treatment, it has long had a bleaker prognosis. I know this only too well, having been diagnosed with TNBC in January 2021. My treatment wrapped up not with a cheery 'all-clear' but with a dark warning to be 'extremely vigilant' for signs of recurrence. This leads to all-consuming fear, anxiety and hypervigilance around everything from back pain, to a cough or a headache – all of which can be signs that the cancer is back. A vaccine that could prevent recurrence sounds too good to be true. Determined to hear it from the horse's mouth, I arrange a Zoom with Dr Amit Kumar, CEO of Anixa, the company developing the vaccine. 'We do believe that, should all the appropriate clinical trials succeed, we can eliminate triple negative breast cancer, which is the most lethal form of the disease,' he says from his office in California. 'Seven years is a tight window but, withi){kind=link}
A ground-breaking new vaccine being trialled in America could save thousands of women from catching triple negative breast cancer (TNBC)
Imagine having a simple vaccination that could protect you from the disease that affects one in seven women in the UK, and is the leading cause of death for women aged 35-49. It sounds like a futuristic fantasy, but recently a flurry of headlines announced that a breast cancer vaccine could be available as soon as 2030.
Let’s look at the facts: the vaccine in question is specifically for triple negative breast cancer (TNBC), and has so far only been tested on women who have had successful treatment for primary TNBC, but are at high risk of recurrence. This type of breast cancer only accounts for around 10-15 per cent of diagnoses, but it’s particularly aggressive and causes 30 per cent of breast cancer deaths.
Known as “triple negative” because it lacks the three main hormone receptors and proteins usually targeted in treatment, it has long had a bleaker prognosis.
I know this only too well, having been diagnosed with TNBC in January 2021. My treatment wrapped up not with a cheery “all-clear” but with a dark warning to be “extremely vigilant” for signs of recurrence. This leads to all-consuming fear, anxiety and hypervigilance around everything from back pain, to a cough or a headache – all of which can be signs that the cancer is back.